Adipogen/Vaspin（人）ELISA试剂盒/AG-45A-0017YTP-KI01/2 x 96孔
商品编号：
AG-45A-0017YTP-KI01
品牌：
Adipogen Inc
市场价：
¥19800.00
美元价：
11880.00
产品分类：
夹心法ELISA
公司分类：
Sandwich_method_ELISA
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| ProductDetails | |
|---|---|
| Synonyms | VisceralADIposeTissue-derivedSerineProteaseInhibitor;SerpinA12;OL-64 |
| ProductType | Kit |
| Properties | |
| ApplicationSet | QuantitativeELISA |
| Specificity | Detectshumanvaspin.Doesnotcross-reactwithhumanRBP4,humanadiponectin,humanNampt,humanleptinorhumanRELM-β. |
| Crossreactivity | Human |
| Quantity | 1x96wells 2x96wells(TwinPlex) |
| Sensitivity | 12pg/ml |
| Range | 0.016to1ng/ml |
| SampleType | CellCultureSupernatant Plasma Serum |
| AssayType | Sandwich |
| DetectionType | Colorimetric |
| ShippingandHandling | |
| Shipping | BLUEICE |
| ShortTermStorage | +4°C |
| LongTermStorage | +4°C |
| HandlingAdvice | Afterstandardreconstitution,preparealiquotsandstoreat-20°C. Avoidfreeze/thawcycles. Plateandreagentsshouldreachroomtemperaturebeforeuse. |
| Use/StABIlity | 12monthsafterthedayofmanufacturing.SeeexpirydateonELISAKitbox. |
| Documents | |
| Manual |  DownloadPDF |
| MSDS | DownloadPDF |
| ProductSpecificationSheet | |
| Datasheet | DownloadPDF |
Vaspin(Visceraladiposetissue-derivedserpin;SerpinA12),aserineproteaseinhibitor(serpin),isaninsulin-sensitizingadipocytokinethathasbeenisolatedfrombothvisceralandsubcutaneouswhiteadiposetissue.Basedonrecentfindings,vaspinissuggestedtoregulateimmuneresponsesandinflammationandwasfoundtobecorrelatedwithvariousmetabolicparameters.Humanvaspinbloodlevelsaresignificantlyincreasedintype2diabetesmellitusandobesepatients.ThusvaspinmayrepresentanovelbioMarkerforobesityandimpairedinsulinsensitivityandmightserveasanewtherapeutictargetofmetabolicsyndrome.
ProductReferences
- Serumvaspinconcentrationsinhumanobesityandtype2diabetes:B.S.Youn,etal.;Diabetes57,372(2008)
- Serumlevelsoftheadipokinevaspininrelationtometabolicandrenalparameters:J.Seeger,etal.;J.Clin.Endocrinol.Metab.93,247(2008)
- MetformindecreasestheAdipokineVaspininoverweightwomenwiththepolycysticovarysyndrome:Concomitantimprovementininsulinsensitivityandadecreaseininsulinresistance:B.K.Tan,etal.;Diabetes57,1501(2008)
- Vaspin:anovelserpinwithinsulin-sensitizingeffects:J.Wada;ExpertOpin.Investig.Drugs17,327(2008)
- Vaspinserumconcentrationsinpatientswithcarotidstenosis:G.Aust,etal.;Atherosclerosis204,262(2009)
- Serumvaspinlevelsintype2diabeticwomeninrelationtomicrovascularcomplications:N.E.Gulcelik,etal.;Eur.J.Endocrinol.160,65(2009)
- SerumVisceralAdiposeTissue–DerivedSerineProteaseInhibitorConcentrationsinHumanObesityandPolycysticOvarySyndrome:H.F.Escobar-Morreale,etal.;DiabetesCare32,e6(2009)
- Low-dosepioglitazoneandlow-doseflutamideaddedtometforminandoestro-progestagensforhyperinsulinaemicwomenwithandrogenexcess:add-onbenefitsdisclosedbyarandomizeddouble-placebostudyover24months:L.Ibanez,etal.;Clin.Endocrinol.(Oxf)71,351(2009)
- Preliminaryreport:circulatinglevelsoftheadipokinevaspiningestationaldiabetesmellitusandpreeclampsia:H.Stepan,etal.;Metabolism59,1054(2010)
- CircadianRhythmofSerumVaspininHealthyMaleVolunteers:RelationtoMeals:E.Jeong,etal.;J.Clin.Endocrinol.Metab.95,1869(2010)
- SerumVaspinConcentrationsinRelationtoInsulinSensitivityFollowingRYGB-InducedWeightLoss:A.Handisurya,etal.;Obes.Surg.20,198(2010)
- Serumchemerinandvaspininnon-alcoholicfattyliverdisease:M.Kukla,etal.;Scand.J.Gastroenterol.45,235(2010)
- Chemerin,vaspinandinsulinresistanceinchronichepatitisC:M.Kukla,etal.;J.ViralHepat.17,661(2010)
- Combinedeffectsofbodymassindexandcardio/respiratoryfitnessonserumvaspinconcentrationsinKoreanyoungmen:J.K.Chou,etal.;Eur.J.Appl.Physiol.108,347(2010)
- AssociationbetweenserumvaspinconcentrationsandvisceraladiposetissueinKoreansubjects:H.M.Chang,etal.;Metabolism59,1276(2010)
- Reducedserumvaspinconcentrationsinobesechildrenfollowingshorttermintensivelifestylemodification:M.K.Lee,etal.;Clin.Chim.Acta411,381(2010)
- Effectsofweightreductiononserumvaspinconcentrationsinobesesubjects:modificationbyinsulinresistance:H.M.Chang,etal.;Obesity(SilverSpring)18,2105(2010)
- Circulatingvaspinisunrelatedtoinsulinsensitivityinacohortofnondiabetichumans:C.vonLoeffelholz,etal.;Eur.J.Endocrinol.162,507(2010)
- Vaspinandomentin:newadipokinesdifferentiallyregulatedatthesiteofinflammationinrheumatoidarthritis:L.Senolt,etal.;Ann.Rheum.Dis.69,1410(2010)
- Comparisonoforlistattreatmentandplaceboinobesetype2diabeticpatients:G.Derosa,etal.;Expert.Opin.Pharmacother.11,1971(2010)
- Comparisonbetweenorlistatplusl-carnitineandorlistataloneoninflammationparametersinobesediabeticpatients:G.Derosa,etal.;Fundam.Clin.Pharmacol. 25,642(2011)
- Vaspinandvisfatin/Namptareinterestinginterrelatedadipokinesplayingaroleinthepathogenesisoftype2diabetesmellitus:H.O.El-Mesallamy,etal.;Metabolism60,63(2011)
- Effectsofcombinationofsibutramineandl-carnitinecomparedwithsibutraminemonotherapyoninflammatoryparametersindiabeticpatients:G.Derosa,etal.;Metabolism60,421(2011)
- Serumvisfatinandvaspinlevelsinprepubertalchildren:effectofobesityandweightlossafterbehaviormodificationsontheirsecretionandrelationshipwithglucosemetabolism:G.A.Martos-Moreno,etal.;Int.J.Obes.(Lond)35, 1355(2011)
- Omentin-1andvaspinarepresentinthefetusandneonate,andperinatalconcentrationsaresimilarinnormalandgrowth-restrictedpregnancies:D.D.Briana,etal.;Metabolism60,486(2011)
- Vaspinisrelatedtogender,pubertyanddeterioratinginsulinsensitivityinchildren:A.Körner,etal.;Int.J.Obes.(Lond)35,578(2011)
- Differentactionsoflosartanandramiprilonadiposetissueactivityandvascularremodelingbiomarkersinhypertensivepatients:G.Derosa,etal.;Hypertens.Res.34,145(2011)
- Lifestylemodificationincreasescirculatingadiponectinconcentrationsbutdoesnotchangevaspinconcentrations:S.M.Kim,etal.;Metabolism60,1294(2011)
- AdipokineprofileismodulatedinsubcutaneousadiposetissuebyTNF{alpha}inhibitorsinpatientswithrheumatoidarthritis:L.Senolt,etal.;Ann.Rheum.Dis.70,2054(2011)
- Newadipokinesvaspinandomentin.Circulatinglevelsandgeneexpressioninadiposetissuefrommorbidlyobesewomen:T.Auguet,etal.;BMCMed.Genet.12,60(2011)
- SerumvaspinandC-reactiveproteinlevelsinwomenwithpolycysticovariesandpolycysticovarysyndrome:E.Cakal,etal.;Gynecol.Endocrinol.27,491(2011)
- Serumvaspinlevelsinhypothyroidpatients:N.Cinar,etal.;Eur.J.Endocrinol.165,563(2011)
- CorrelationofCirculatingOmentin-1withBoneMineralDensityinMultipleSclerosis:TheCrosstalkbetweenBoneandAdiposeTissue:M.Assadi,etal.;PLoSOne6,e24240(2011)
- VaspinplasmaconcentrationsandmRNAexpressionsinpatientswithstableandunstableanginapectoris:H.L.Li,etal.;Clin.Chem.Lab.Med.49,1547(2011)
- Short-termeffectofweightlossthroughrestrictivebariatricsurgeryonserumlevelsofvaspininmorbidlyobesesubjects:A.Golpaie,etal.;Eur.CytokineNetw.22,181(2011)
- Associationbetweenhepaticangiogenesisandserumadipokineprofileinnon-obesechronichepatitisCpatients:M.Kukla,etal.;Pol.J.Pathol.62,218(2011)
- CirculatinglevelsoftheadipocytokinesvaspinandomentininpatientswithKawasakidisease:A.FiorAvanti,etal.;Rheumatol.Int. 32, 1481(2012)
- Twopatternsofadipokineandotherbiomarkerdynamicsinalong-termweightlossintervention:M.Blüher,etal.;DiabetesCare35,342(2012)
- Increasedlevelsandadiposetissueexpressionofvisfatininmorbidlyobesewomen.Therelationshipwithpro-inflammatorycytokines:X.Terra,etal.;Clin.Endocrinol.(Oxf.)77,691(2011)
- Treatment-specificchangesincirculatingadipocytokines:acomparisonbetweentumournecrosisfactorblockadeandglucocorticoidtreatmentforrheumatoidarthritis:R.Klaasen,etal.;Ann.Rheum.Dis.71,1510(2012)
- TheImpactofType2DiabetesonCirculatingAdipokinesinPatientswithMetabolicSyndrome:K.Schindler,etal.;Obes.Facts5,270(2012)
- Vaspin-alinkofobesityandpsoriasis?:A.Saalbach,etal.;Exp.Dermatol.21,309(2012)
- Post-ResistanceExerciseResponseofVaspinAdipocytokinanditsRelationtoInsulinandGlucoseLevelsinOverweightWomen:M.Ghahramani,etal.;Middle-EastJ.Sci.Res.11,1328(2012)
- Geneticvariationinthevaspingeneaffectscirculatingserumvaspinconcentrations:J.Breitfeld,etal.;Int.J.Obes.37,861(2013)
- AssociationofvaspingenepolymorphismswithcoronaryarterydiseaseinChinesepopulationandfunctionstudy:H.L.Li,etal.;Clin.Chim.Acta.415,233(2013)
- Vaspinconcentrationinobesity,impairedglucosetoleranceandType2diabetesinEgypt:H.B.Atya,etal.;Adv.Res.Biol.Sci.1,6(2013)
- Associationsbetweentissuevisfatin/nicotinamide,phosphoribosyltransferase(Nampt),retinolbindingprotein-4,andvaspinconcentrationsandinsulinresistanceinmorbidlyobesesubjects:Z.Goktas,etal.;MediatorsInflamm.2013,861496(2013)
- Identificationofadipokineclustersrelatedtoparametersoffatmass,insulinsensitivityandinflammation:G.Flehmig,etal.;PLoSOne9,e99785(2014)
- Expressionofvaspininthejointandthelevelsintheserumandsynovialfluidofpatientswithosteoarthritis:J.-P.Bao,etal.;Int.J.Clin.Exp.Med.7,3447(2014)
- Associationofvaspinwithmetabolicsyndrome:Thepivotalroleofinsulinresistance:A.Esteghmatai,etal.;Diabet.Metab.38,143(2014)
- Assessmentofserumchemerin,vaspinandomentin-1levelsinpatientswithpolycysticovarysyndrome:Y.Guvenc,etal.;J.Int.Med.Res.44,796(2016)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
